55726-47-1

Basic information

• Product Name: Enocitabine
• Synonyms: N-(1-BETA-D-ARABINOFURANOSYL-1,2-DIHYDRO-2-OXO-4-PYRIMIDINYL)DOCOSANAMIDE;NSC-239336;SUNRABIN;BEHENOYLCYTOSINE ARABINOSIDE;BH-AC;ENOCITABINE;n-(1-beta-d-arabinofuranosyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-docosanamid;n(sup4)-behenoyl-1-beta-d-arabinofuranosylcytosine
• CAS NO: 55726-47-1
• Molecular Formula: C31H55N3O6
• Molecular Weight: 565.78
• EINECS: 1312995-182-4
• Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 55726-47-1.mol

Chemical Properties

• Melting Point: 141-142°C
• Boiling Point: 630.87°C (rough estimate)
• Flash Point: °C
• Appearance: /
• Density: 1.0967 (rough estimate)
• Refractive Index: 1.7800 (estimate)
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly, Heated), Methanol (Slightly, Heated), THF (Slightly, Heated, Son
• CAS DataBase Reference: Enocitabine(CAS DataBase Reference)
• NIST Chemistry Reference: Enocitabine(55726-47-1)
• EPA Substance Registry System: Enocitabine(55726-47-1)

Safety Data

• Hazardous Substances Data: 55726-47-1(Hazardous Substances Data)

Usage

Uses

Used in Oncology:
Enocitabine is used as an antineoplastic agent, specifically as a derivative of cytarabine, for the treatment of various types of cancer. Its increased resistance to deamination compared to cytarabine enables more efficient conversion into an active cytotoxic metabolite, making it a valuable option in cancer treatment.
Used in Pharmaceutical Industry:
Enocitabine is used as an active pharmaceutical ingredient in the development of cancer treatment drugs. Its unique properties, such as greater resistance to deamination, make it a promising candidate for the creation of more effective and targeted cancer therapies.
Used in Research and Development:
Enocitabine is utilized as a research compound in the field of oncology, where scientists study its properties, mechanisms of action, and potential applications in cancer treatment. This research can lead to the development of new drugs and therapies that build upon the unique characteristics of enocitabine.

Originator

Asahi (Japan)

InChI:InChI=1/C31H55N3O6/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-27(36)32-26-22-23-34(31(39)33-26)30-29(38)28(37)25(24-35)40-30/h22-23,25,28-30,35,37-38H,2-21,24H2,1H3,(H,32,33,36,39)/t25-,28-,29+,30-/m1/s1

Relevant articles and documents

TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER

A blend of at least three polymers, including a soluble polyvinylpyrrolidone, in combination with a drug provides a pressure-sensitive adhesive composition for a transdermal drug delivery system in which the drug is delivered from the pressure-sensitive adhesive composition and through dermis when the pressure-sensitive adhesive composition is in contact with human skin. Soluble polyvinylpyrrolidone increases the solubility of drug without negatively affecting the adhesivity of the composition or the rate of drug delivery from the pressure-sensitive adhesive composition

N4 -acylarabinonucleosides

An N4 -acyl-1-β-D-arabinofuranosylcytosine having the following formula SPC1 Wherein R is an aliphatic acyl group having 3 to 35 carbon atoms. The compounds of this invention are useful as a cancer chemotherapeutic agent for controlling tumors, e.g., in mice, an insecticide, and a fungicidal surface active agent.